Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The 2025 application process for changes in the Swiss procedure classification cancelled

On May 15, 2025, the Swiss Federal Statistics Office (Bundesamt für Statistik, BFS) announced that the 2025 application process for the further development of the Swiss Classification of Surgical Procedures (CHOP) and the Swiss Coding Manual is cancelled due to the federal government's cost-saving measures resulting in shortage of personnel resources.

The development of the CHOP and the Coding Manual for 2026 will be based on applications from the 2024 application process, previously deferred applications, and necessary corrections.

The CHOP and Coding Manual for 2027 will only be developed based on deferred applications and necessary corrections.

According to BFS, the situation with the 2026 application process remains uncertain. Depending on how the situation evolves, similar or additional measures can be expected.

See the full details in German here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.